BSE · 540468
KMS Medisurgi Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹14 Cr with net profit ₹0 Cr — a 3.15% net margin, versus 3.25% the period before.
Shareholding
As of 2026-06-30
- Promoter74.42%
- Public25.58%
63 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.05× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #1 of 85 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,27,968 Cr | 60.82 | 13.46 | 20.48% | 7.91% |
| Max Healthcare Institute Ltd. | ₹1,01,088 Cr | 67.53 | 9.41 | 13.42% | 16.73% |
| Manipal Health Enterpri Limited | ₹96,450 Cr | 102.84 | 5.87 | 10.59% | 7.81% |
| Fortis Healthcare Ltd. | ₹68,131 Cr | 63.87 | 6.88 | 10.53% | 11.02% |
| Aster DM Quality Care Ltd. | ₹66,888 Cr | 172.44 | 15.89 | 8.48% | 6.54% |
| Global Health Limited | ₹39,245 Cr | 68.56 | 9.91 | 14.05% | 11.88% |
| Narayana Hrudayalaya Ltd. | ₹39,027 Cr | 45.28 | 8.6 | 17.76% | 9% |
| Krishna Institute of Medical Sciences Ltd. | ₹32,458 Cr | 155.49 | 8.66 | 10.74% | 4.85% |
| Dr. Lal Path Labs Ltd. | ₹32,172 Cr | 57.2 | 12.83 | 20.13% | 18.75% |
| Poly Medicure Ltd. | ₹17,743 Cr | 55.45 | 5.7 | 10.37% | 15.77% |
| KMS Medisurgi Limited(this company) | — | — | — | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashKMS Medisurgi Limited has a market capitalization of Rs 47 Cr. The company reported revenue of Rs 13.97 Cr in the latest period. Promoter holding stands at 74.42% as of June 30, 2026. The debt-to-equity ratio is 0.09. Public shareholding is 25.58% with 63 shareholders.
Positives
- +Promoter holding is high at 74.42% as of June 30, 2026.
- +The debt-to-equity ratio is low at 0.09.
- +Revenue increased to Rs 13.97 Cr in March 2024 from Rs 7.61 Cr in March 2021.
Negatives
- −Net profit decreased to Rs 0.45 Cr in March 2024 from Rs 0.57 Cr in March 2023.
- −Earnings per share (EPS) declined to Rs 1.38 in March 2024 from Rs 1.74 in March 2023.
- −No quarterly results have been disclosed in the provided data.
- −The trailing twelve-month PE ratio, book value, EPS, ROE, ROCE, and profit margin are not available.
Financial Performance
KMS Medisurgi Limited's revenue increased to Rs 13.97 Cr in March 2024 from Rs 11.04 Cr in March 2023. Net profit for March 2024 was Rs 0.45 Cr, down from Rs 0.57 Cr in March 2023. Earnings per share (EPS) were Rs 1.38 in March 2024, compared to Rs 1.74 in March 2023.
Profitability & Returns
The company's net profit was Rs 0.45 Cr in March 2024. Earnings before interest, taxes, depreciation, and amortization (EBITDA) was Rs 0.62 Cr in March 2024. Net profit decreased to Rs 0.44 Cr in March 2025 compared to Rs 0.45 Cr in March 2024, with EPS at Rs 1.33 in March 2025.
Balance Sheet
KMS Medisurgi Limited has a debt-to-equity ratio of 0.09. This indicates a low level of debt relative to equity. No figures for detailed assets or liabilities were provided in the available data.
Ownership & Pledges
Public shareholding is 25.58% with 63 shareholders. There were no promoter share pledges reported in the available data for the specified period. FII and DII holdings were 0% as of June 30, 2026.
Data as of — price: 2026-09-11 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.